Traws Pharma Secures $72.6 Million Funding to Advance Bird Flu Treatment Development Traws Pharma raises $72.6 million to develop Tivoxavir Marboxil, an oral treatment for H5N1 Bird Flu, amid rising disease concerns.

Traws Pharma Secures $72.6 Million Funding to Advance Bird Flu Treatment Development #USA #Newtown #Traws_Pharma #Tivoxavir_Marboxil #H5N1_Bird_Flu